請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81201完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 林晉玄(Ching-Hsuan Lin) | |
| dc.contributor.author | Shi Qian Lew | en |
| dc.contributor.author | 廖世軒 | zh_TW |
| dc.date.accessioned | 2022-11-24T03:35:53Z | - |
| dc.date.available | 2021-08-16 | |
| dc.date.available | 2022-11-24T03:35:53Z | - |
| dc.date.copyright | 2021-08-16 | |
| dc.date.issued | 2021 | |
| dc.date.submitted | 2021-08-11 | |
| dc.identifier.citation | 1. Lockhart, S.R., et al., Emerging and reemerging fungal infections. Semin Diagn Pathol, 2019. 36(3): p. 177-181. 2. Richardson, M., et al., Changing epidemiology of systemic fungal infections. Clin Microbiol Infect, 2008. 14 Suppl 4: p. 5-24. 3. Sardi, J.C.O., et al., Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options. J Med Microbiol, 2013. 62(Pt 1): p. 10-24. 4. Stop neglecting fungi. Nat Microbiol, 2017. 2: p. 17120. 5. G. D. Brown, et al., Hidden Killers Human Fungal infections. Sci. Transl. Med., 2012. 4(165rv13). 6. Yang, Y., et al., Prevention of Oral Candidiasis After Free Flap Surgery: Role of 3%Sodium Bicarbonate Saline in Oral Care. J Oral Maxillofac Surg, 2017. 75(3): p. 641-647. 7. Erdogan, A., et al., Small intestinal fungal overgrowth. Curr Gastroenterol Rep, 2015. 17(4): p. 16. 8. Hesstvedt, L., et al., The impact of age on risk assessment, therapeutic practice and outcome in candidemia. Infect Dis (Lond), 2019. 51(6): p. 425-434. 9. Limper, A.H., et al., Fungal infections in HIV/AIDS. The Lancet Infectious Diseases, 2017. 17(11): p. e334-e343. 10. Sudbery, P., et al., The distinct morphogenic states of Candida albicans. Trends Microbiol, 2004. 12(7): p. 317-24. 11. Gulati, M. et al., Candida albicans biofilms: development, regulation, and molecular mechanisms. Microbes Infect, 2016. 18(5): p. 310-21. 12. Richard A.C., et al., Candida and Candidiasis, Second Edition. 2 ed. 2012: Society for General Microbiology. 13. Segal, B.H., Immunotherapy for fungal infections. Clinical Infectious Diseases, 2006. 42: p. 507-515. 14. Bondaryk, M., et al., Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development. Postepy Dermatol Alergol, 2013. 30(5): p. 293-301. 15. Spampinato, C., et al., Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int, 2013. 2013: p. 204237. 16. Martins, N., et al., Candidiasis: predisposing factors, prevention, diagnosis and alternative treatment. Mycopathologia, 2014. 177(5-6): p. 223-40. 17. Wang, Z.K., et al., Review article: fungal microbiota and digestive diseases. Aliment Pharmacol Ther, 2014. 39(8): p. 751-66. 18. Magill, S.S., et al., Multistate point-prevalence survey of health care-associated infections. N Engl J Med, 2014. 370(13): p. 1198-208. 19. Ruan, S.Y., Invasive Candidiasis An Overview from Taiwan. J Formos Med Assoc, 2009. 108(6): p. 443-451. 20. Silva, S., et al., Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev, 2012. 36(2): p. 288-305. 21. Negri, M., et al., Insights into Candida tropicalis nosocomial infections and virulence factors. Eur J Clin Microbiol Infect Dis, 2012. 31(7): p. 1399-412. 22. Hii, I.M., et al., Resistance rates of non-albicans Candida infections in Taiwan after the revision of 2012 Clinical and Laboratory Standards Institute breakpoints. Infect Drug Resist, 2019. 12: p. 235-240. 23. Mayer, F.L., et al., Candida albicans pathogenicity mechanisms. Virulence, 2013. 4(2): p. 119-28. 24. Chai, L.Y., et al., Candida tropicalis in human disease. Crit Rev Microbiol, 2010. 36(4): p. 282-98. 25. Zhai, L., et al., Isolation and identification of Candida tropicalis in sows with fatal infection: a case report. BMC Vet Res, 2021. 17(1): p. 108. 26. Nucci, M., et al., Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis, 2007. 58(1): p. 77-82. 27. Liu, W.L., et al., Clinical characteristics of Candida tropicalis fungaemia with reduced triazole susceptibility in Taiwan: a multicentre study. Int J Antimicrob Agents, 2019. 53(2): p. 185-189. 28. Lewis, R.E., Current concepts in antifungal pharmacology. Mayo Clin Proc, 2011. 86(8): p. 805-17. 29. Whaley, S.G., et al., Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front Microbiol, 2016. 7: p. 2173. 30. Lamb, D., et al., Molecular aspects of azole antifungal action and resistance. Drug Resist Updat, 1999. 2(6): p. 390-402. 31. Mohamed, I.A., et al., 1-Aryl-3-(1H-imidazol-1-yl)propan-1-ol esters synthesis, anti-Candida potential and molecular modeling studies. Chemistry Central Journal, 2013. 7: p. 168. 32. A.J., Sucher, et al., Echinocandins: The Newest Class of Antifungals. Annals of Pharmacotherapy, 2009. 43: p. 1647-1657. 33. Loh, B.S., et al., 'Illuminating' Echinocandins' Mechanism of Action. ACS Cent Sci, 2020. 6(10): p. 1651-1653. 34. Dominique S., Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infectious Diseases 2002. 2: p. 73-85. 35. Mahmoud A.G., Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance. Clin Microbiol Reviews, 1999. 12(4): p. 501-517. 36. George S., et al., Gabriel G Perrone and Charles Oliver Morton, The polyene antifungals, amphotericin B and nystatin, cause cell death in Saccharomyces cerevisiae by a distinct mechanism to amphibian-derived antimicrobial peptides. Annals of Clinical Microbiology and Antimicrobials, 2014. 13(18). 37. Dixon DM, ed. Antifungal Agents. 4 ed. 1996, Medical Microbiology. 38. Kyriakidis, I., et al., Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf, 2017. 16(2): p. 149-165. 39. Viviani, M.A., Flocytosine—what is its future. Antimicrob Agents Chemother, 1995. 35: p. 241-244. 40. Vermes, A., Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Antimicrob Agents Chemother, 2000. 46: p. 171-179. 41. Paul, S., et al., Dynamics of in vitro development of azole resistance in Candida tropicalis. J Glob Antimicrob Resist, 2020. 22: p. 553-561. 42. Garcia, E., et al., Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother, 2008. 52(11): p. 4181-3. 43. Choi, M.J., et al., Resistance Mechanisms and Clinical Features of Fluconazole-Nonsusceptible Candida tropicalis Isolates Compared with Fluconazole-Less-Susceptible Isolates. Antimicrob Agents Chemother, 2016. 60(6): p. 3653-61. 44. Kothavade, R.J., et al., Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol, 2010. 59(Pt 8): p. 873-880. 45. Yang, Y.L., et al., Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006. Diagn Microbiol Infect Dis, 2008. 61(2): p. 175-80. 46. Cowen, L.E., et al., Mechanisms of Antifungal Drug Resistance. Cold Spring Harb Perspect Med, 2014. 5(7): p. a019752. 47. Sanglard, D., Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother, 1995. 39(11): p. 2378-2386. 48. Lamping, E., et al., Characterization of three classes of membrane proteins involved in fungal azole resistance by functional hyperexpression in Saccharomyces cerevisiae. Eukaryot Cell, 2007. 6(7): p. 1150-65. 49. Sanglard, D., et al., Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res, 2009. 9(7): p. 1029-50. 50. White, T.C., et al., Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother, 2002. 46(6): p. 1704-13. 51. Perea, S., et al., Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother, 2001. 45(10): p. 2676-84. 52. White, T.C., Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother, 1997. 41(7): p. 1482-1487. 53. Franz, R., Multiple Molecular Mechanisms Contribute to a Stepwise development of fluconazole resistance in clinical candida albicans strains. Antimicrob Agents Chemother, 1998. 42(12): p. 3065-3072. 54. Garcia, E., et al., Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother, 2009. 53(1): p. 112-22. 55. Garcia, E., et al., Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother, 2009. 53(9): p. 3690-9. 56. Katiyar, S.K., et al., Role for Fks1 in the intrinsic echinocandin resistance of Fusarium solani as evidenced by hybrid expression in Saccharomyces cerevisiae. Antimicrob Agents Chemother, 2009. 53(5): p. 1772-8. 57. Johnson, M.E., et al., Edlind, New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemother, 2011. 55(8): p. 3774-81. 58. Douglas L. M., et al., ed. Antimicrobial Drug Resistance. Vol. 1. 2017, Springer. 59. Hitchcock, C.A., The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J Med Vet Mycol., 1987. 25(1): p. 29-37. 60. Subden, R.E., Eburicol, lichesterol, ergosterol, and obtusifoliol from polyene antibiotic-resistant mutants of Candida albicans. Can J Microbiol., 1977. 23(6): p. 751-754. 61. Cheng, M.F., et al., Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999. Diagn Microbiol Infect Dis, 2004. 48(1): p. 33-7. 62. Chaffin, W.L., Cell Wall and Secreted Proteins of Candida albicans identification, function and expression. Microbiology and Molecular Biology, 1998. 62(1): p. 130-180. 63. Duran, A., et al., Fungal cell wall biogenesis: building a dynamic interface with the environment. Microbiology (Reading), 2004. 150(Pt 10): p. 3099-103. 64. Klis, F.M., Covalently linked wall proteins in ascomycetous fungi. Yeast, 2010. 27(8): p. 489-493. 65. Peter, N.L., et al., Cell Wall Architecture in Yeast new structure and new challenge. Journal of Bacteriology, 1998. 180(15): p. 3735-3740. 66. Nafsika, H.G., et al., The fungal cell wall as a drug target.pdf. Trends Microbiol, 1995. 3(3): p. 98-104. 67. Sahar, H., et al., Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents. Future Medicinal Chemistry, 2019. 11(8): p. 869-883. 68. Dichtl, K., et al., Cell wall integrity signalling in human pathogenic fungi. Cell Microbiol, 2016. 18(9): p. 1228-38. 69. Jendretzki, A., et al., How do I begin? Sensing extracellular stress to maintain yeast cell wall integrity. Eur J Cell Biol, 2011. 90(9): p. 740-4. 70. Levin, D.E., Regulation of cell wall biogenesis in Saccharomyces cerevisiae: the cell wall integrity signaling pathway. Genetics, 2011. 189(4): p. 1145-75. 71. Chattaway, F.W., et al., Cell wall composition of the mycelial and blastospore forms of Candida albicans. J Gen Microbiol. , 1968. 51(3): p. 367-376. 72. Bowman, S.M., et al., The structure and synthesis of the fungal cell wall. Bioessays, 2006. 28(8): p. 799-808. 73. Garcia-Rubio, R., et al., The Fungal Cell Wall: Candida, Cryptococcus, and Aspergillus Species. Front Microbiol, 2019. 10: p. 2993. 74. Hannah, E.B., et al., Chitin: A 'Hidden Figure' in the Fungal Cell Wall. Curr Top Microbiol Immunol, 2020. 425: p. 83-111. 75. Mora-Montes, H.M., ed. The Fungal Cell Wall. 2013, Nova Science Publishers Inc. 1-26. 76. Roncero, C., The genetic complexity of chitin synthesis in fungi. Curr Genet, 2002. 41(6): p. 367-78. 77. Li, M., et al., Evolution and Functional Insights of Different Ancestral Orthologous Clades of Chitin Synthase Genes in the Fungal Tree of Life. Front Plant Sci, 2016. 7: p. 37. 78. Lenardon, M.D., et al., Chitin synthesis and fungal pathogenesis. Curr Opin Microbiol, 2010. 13(4): p. 416-23. 79. Carol A.M., et al., Chs1 of Candida albicans is an essential chitin synthase required for synthesis of the septum and for cell integrity. mol Microbiol, 2001. 39(5): p. 1414-1426. 80. Bulawa, C.E., Attenuated virulence of chitin-deficient mutants of Candida albicans. Proceedings of the National Academy of Sciences of the United States of America, 1995. 92: p. 10570-10574. 81. Zhang, P., et al., Snf1AMPK affects cell wall integrity through regulating the transcription of cell wall as sembly-related genesin Saccharomyces cerevisiae. Acta Microbiologica Sinica, 2016. 56(7): p. 1132-1140. 82. Lesage, G., et al., Cell wall assembly in Saccharomyces cerevisiae. Microbiol Mol Biol Rev, 2006. 70(2): p. 317-43. 83. Yoshimi, A., et al., Function and Biosynthesis of Cell Wall alpha-1,3-Glucan in Fungi. J Fungi (Basel), 2017. 3(4). 84. Yang, F., et al., Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling. Antimicrob Agents Chemother, 2017. 61(5). 85. Hall, R.A., et al., Mannosylation in Candida albicans: role in cell wall function and immune recognition. Mol Microbiol, 2013. 90(6): p. 1147-61. 86. Shibata, N., et al., Chemical structure of the cell-wall mannan of Candida albicans serotype A and its difference in yeast and hyphal forms. Biochem J, 2007. 404(3): p. 365-72. 87. Sanz, P., AMPK in Yeast: The SNF1 (Sucrose Non-fermenting 1) Protein Kinase Complex. Exp Suppl., 2016. 107: p. 353-374. 88. David, C., et al., A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett., 1987. 223(2): p. 217-222. 89. Amodeo, G.A., et al., Crystal structure of the heterotrimer core of Saccharomyces cerevisiae AMPK homologue SNF1. Nature, 2007. 449(7161): p. 492-5. 90. Rong, J., et al., Glucose regulates protein interactions within the yeast SNF1 protein kinase complex. Genes Dev, 1996. 10: p. 3105-3115. 91. Vincent, O., et al., Subcellular localization of the Snf1 kinase is regulated by specific beta subunits and a novel glucose signaling mechanism. Genes Dev, 2001. 15(9): p. 1104-14. 92. Hedbacker, K., et al., Cyclic AMP-dependent protein kinase regulates the subcellular localization of Snf1-Sip1 protein kinase. Mol Cell Biol, 2004. 24(5): p. 1836-43. 93. Viana, R., et al., A conserved sequence immediately N-terminal to the Bateman domains in AMP-activated protein kinase gamma subunits is required for the interaction with the beta subunits. J Biol Chem, 2007. 282(22): p. 16117-25. 94. Mayer, F.V., et al., ADP regulates SNF1, the Saccharomyces cerevisiae homolog of AMP-activated protein kinase. Cell Metab, 2011. 14(5): p. 707-14. 95. Coccetti, P., et al., Conventional and emerging roles of the energy sensor Snf1/AMPK in Saccharomyces cerevisiae. Microb Cell, 2018. 5(11): p.482-494 96. Wilson, W.A., et al., Glucose repression/derepression in budding yeast: SNF1 protein kinase is activated by phosphorylation under derepressing conditions, and this correlates with a high AMP:ATP ratio. Current Biology, 1996. 6(11): p. 1426-1434. 97. Chen, J.K., et al., N-acetyl glucosamine obtained from chitin by chitin degrading factors in Chitinbacter tainanesis. Int J Mol Sci, 2011. 12(2): p. 1187-95. 98. Elisa, M.V., et al., N-Acetylglucosamine Metabolism promotes survival of Candida Albicans in the Phagasome. mSphere 2, 2017. 2(5): p. 00357-17. 99. Min, K., et al., Genetic Analysis of NDT80 Family Transcription Factors in Candida albicans Using New CRISPR-Cas9 Approaches. mSphere 2018. 3(6): p. e00545-18. 100. Naseem, S., et al., Regulation of Hyphal Growth and N-Acetylglucosamine Catabolism by Two Transcription Factors in Candida albicans. Genetics, 2017. 206(1): p. 299-314. 101. Song, Y.D., et al., Candida tropicalis RON1 is required for hyphal formation, biofilm development, and virulence but is dispensable for N-acetylglucosamine catabolism. Med Mycol, 2021. 59(4): p. 379-391. 102. Su, C., et al., N-acetylglucosamine sensing by a GCN5-related N-acetyltransferase induces transcription via chromatin histone acetylation in fungi. Nat Commun, 2016. 7: p. 12916. 103. Kanai, T., et al., Expression of the SNF1 gene from Candida tropicalis is required for growth on various carbon source, including glucose. Arch Microbiol, 1999. 172: p. 256-263. 104. Smith, D.L., et al., Calorie restriction extends the chronological lifespan of Saccharomyces cerevisiae independently of the Sirtuins. Aging Cell, 2007. 6(5): p. 649-62. 105. Wierman, M.B., Caloric Restriction Extends Yeast Chronological Life Span by Optimizing the Snf1 (AMPK) Signaling Pathway. Mol Cell Biol, 2017. 37(13). 106. Jean F., et al., Reserve carbohydrates metabolism in the yeast Saccharomyces cerevisiae. FEMS Microbiol Rev, 2001: p. 125-145. 107. Francois, J.M., A simple method for quantitative determination of polysaccharides in fungal cell walls. Nat Protoc, 2006. 1(6): p. 2995-3000. 108. Thompson, D.S., et al., Coevolution of morphology and virulence in Candida species. Eukaryot Cell, 2011. 10(9): p. 1173-82. 109. Simpson, L.K., et al., A reversible liquid drop aggregation controls glucose response in yeast. Curr Genet, 2018. 64(4): p. 785-788. 110. Kayikci, O., et al., Glucose repression in Saccharomyces cerevisiae. FEMS Yeast Res, 2015. 15(6). 111. Alby, K., et al., Homothallic and heterothallic mating in the opportunistic pathogen Candida albicans. Nature, 2009. 460(7257): p. 890-893. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/81201 | - |
| dc.description.abstract | 熱帶念珠菌(Candida tropicalis)是熱帶及亞熱帶地區常見的伺機性致病真菌並位居台灣院內感染菌種排名的第7名。近年來，抗真菌藥物的大量使用造成抗藥性菌株的數目逐年趨升，增加了治療熱帶念珠菌感染的難度。醣類代謝為真菌維持基礎生理活動重要的過程，並被證實與細胞壁合成相關。過去文獻發現釀酒酵母菌 (Saccharomyces cerevisiae) 及白色念珠菌 (Candida albicans) 的SNF4基因功能能感應周遭環境的葡萄糖多寡。在低葡萄糖環境下，Snf1-Snf4 蛋白質複合體 (Snf1-Snf4 protein complex) 能活化非葡萄糖碳源代謝路徑，以提高生存率。然而，SNF4 在念珠菌的功能並不清楚。因此，本研究欲透過熱帶念珠菌SNF4基因，從醣代謝的角度切入，探討其對抗真菌藥物的耐受性及致病機制。結果顯示，SNF4基因除了負責了熱帶念珠菌的醣代謝路徑，更維持其細胞壁完整性，進而影響熱帶念珠菌致病能力。利用苯酚-硫酸法 (Phenol-Sulphuric acid method) 探討熱帶念珠菌細胞壁多醣類的完整性，發現熱帶念珠菌snf4∆ 突變株細胞壁之多醣類濃度顯著的比野生株及互補株低。RT-qPCR結果顯示，在snf4∆ 突變株，FKS1及FKS2的基因表現量大幅度降低。Fks家族為合成細胞壁上β-葡聚醣 (β-Glucan) 之重要蛋白質並且是caspofungin 抗真菌藥物作用的標地。我的實驗結果證實Snf4 正向調控FKS家族基因表現量，進一步影響細胞壁β-葡聚醣的合成與維持細胞壁完整性；也進一步證實熱帶念珠菌snf4∆突變株對caspofungin抗藥性大幅度降低。以大蠟蛾幼蟲及小鼠進行致病力分析，結果顯示， snf4∆突變株對大蠟蛾幼蟲與小鼠的致病力顯著降低，證實SNF4參與熱帶念珠菌之致病機制。綜合實驗結果，本研究發現SNF4基因不僅參與熱帶念珠菌的非葡萄糖碳源的代謝，也正向調控FKS家族基因以維持其細胞壁之完整性、藥物耐受性與致病力。 | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T03:35:53Z (GMT). No. of bitstreams: 1 U0001-0208202113415400.pdf: 2299268 bytes, checksum: 9aff70a05ae2a09b58d314a597b8f940 (MD5) Previous issue date: 2021 | en |
| dc.description.tableofcontents | 摘要…………………………………………………………………………………………….i Abstract………………………………………………………………………………………. ii 目錄…………………………………………………………………………………………...iv 表目錄…………………………………………………………………………………………v 圖目錄………………………………………………………………………………………...vi 第一章 文獻回顧……………………………………………………………………………...1 第一節 念珠菌所造成之臨床威脅………………………………………………………1 第二節 熱帶念珠菌: 亞熱帶地區非白色念珠菌之首…………………………………..2 第三節 常見之抗真菌藥物………...…………………………………………………….3 第四節 熱帶念珠菌之抗藥性與機制……………………………………………………4 第五節 熱帶念珠菌之細胞壁……………………………………………………………5 第六節 SNF4 基因…………...…………………………………………………………...7 第二章 實驗目的…………………………………………………………………………….10 第三章 材料與方法………………………………………………………………………….12 第四章 實驗結果…………………………………………………………………………….24 第五章 討論………………………………………………………………………………….30 第六章 未來研究方向……………………………………………………………………….35 圖表…………………………………………………………………………………………..36 參考文獻……………………………………………………………………………………..52 附錄…………………………………………………………………………………………..61 | |
| dc.language.iso | zh-TW | |
| dc.subject | 致病力 | zh_TW |
| dc.subject | 熱帶念珠菌 | zh_TW |
| dc.subject | SNF4 | zh_TW |
| dc.subject | 細胞壁完整性 | zh_TW |
| dc.subject | 抗藥性 | zh_TW |
| dc.subject | cell wall integrity | en |
| dc.subject | pathogenicity | en |
| dc.subject | drug resistant | en |
| dc.subject | Candida tropicalis | en |
| dc.subject | SNF4 | en |
| dc.title | 熱帶念珠菌SNF4基因功能之探討 | zh_TW |
| dc.title | Investigation of the role of SNF4 gene in Candida tropicalis | en |
| dc.date.schoolyear | 109-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 羅秀容(Hsin-Tsai Liu),呂俊毅(Chih-Yang Tseng),薛雁冰 | |
| dc.subject.keyword | 熱帶念珠菌,SNF4,細胞壁完整性,抗藥性,致病力, | zh_TW |
| dc.subject.keyword | Candida tropicalis,SNF4,cell wall integrity,drug resistant,pathogenicity, | en |
| dc.relation.page | 69 | |
| dc.identifier.doi | 10.6342/NTU202101993 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2021-08-13 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科技學系 | zh_TW |
| 顯示於系所單位： | 生化科技學系 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0208202113415400.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 2.25 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。